Navigation Links
Fluoride Treatment of Synthetic Bio-material Assists Dental Bone Regeneration
Date:5/2/2013

Lawrence, KS (PRWEB) May 03, 2013

Journal of Oral Implantology – For a successful dental implant, a sufficient amount of jawbone is necessary. Deficient bone must be built up before the procedure. Guided bone regeneration is a common treatment, and bio-materials treated with fluoride are displaying cell proliferation that can improve this process.

The Journal of Oral Implantology reports on a study of bio-resorbable synthetic hydroxyapatite granules used as a bone supplement material. When these granules were exposed to a 4 percent sodium fluoride solution, cell proliferation was increased.

Bone regeneration techniques include the use of artificial materials such as hydroxyapatite and tricalcium phosphate. Implant products are being made with surface coatings or textures that have a biological effect on protein attachment and cell proliferation. When fluoride is added to this surface, it activates osteoblastic, or bone-making, cells and increases the rate of bone regeneration.

In this study, hydroxyapatite granules were treated with a neutral 4 percent sodium fluoride solution. This led to the formation of a reactant resembling calcium fluoride on the surface of the granules. Immediate but slow release of fluoride came from the granules, and the concentration increased over time. Migration of human osteoblast-like MG-63 cells was confirmed when compared to a nonfluoridated control sample.

Fluoride concentrations of 1.0-2.0 parts per million (ppm) showed this positive effect. When the concentration reached 5.0 ppm, however, the opposite effect was observed—the fluoride significantly inhibited cell proliferation.

The authors conclude that the fluoride solution stimulates bone regeneration. The slow release of fluoride from hydroxyapatite granules facilitates osteogenesis, making this a beneficial method to supply fluoride and promote cell proliferation.

Full text of the article, “Fluoride-Treated Bio-Resorbable Synthetic Hydroxyapatite Promotes Proliferation and Differentiation of Human Osteoblastic MG-63 Cells,” Journal of Oral Implantology, Vol. 39, No.1, 2013, is available at http://www.joionline.org/doi/full/10.1563/AAID-JOI-D-10-00175.

###

About Journal of Oral Implantology
The Journal of Oral Implantology is the official publication of the American Academy of Implant Dentistry and of the American Academy of Implant Prosthodontics. It is dedicated to providing valuable information to general dentists, oral surgeons, prosthodontists, periodontists, scientists, clinicians, laboratory owners and technicians, manufacturers, and educators. The JOI distinguishes itself as the first and oldest journal in the world devoted exclusively to implant dentistry. For more information about the journal or society, please visit: http://www.joionline.org

Media Contact:
Bridget Lamb
Allen Press, Inc.
800/627-0326 ext. 248
blamb(at)allenpress(dot)com

Read the full story at http://www.prweb.com/releases/2013/5/prweb10682953.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Removing Fluoride: What's the Fuss?
2. Zion Health’s Native Remedy-Natural Clay Toothpaste without Fluoride; Now Available at Marquette Food Co-op
3. Zion Health Announces Native Remedy-Natural Clay Toothpaste without Fluoride formulated to help Prevent Gum Disease. Now Available At Whole Foods Market in Lafayette, CA.
4. Jacksonville, FL Periodontist, Dr. Richard E. Aguila, Offers Laser Gum Disease Treatment
5. Girls With Autism May Need Different Treatments Than Boys
6. Large genomic study identifies endometrial cancer subtypes, treatment opportunities
7. Women's Excellence in Menopause Now Offering Treatment Options for Decreased Sex Drive near Rochester Hills, Michigan; Natural Therapy Available via Bioidentical Hormones
8. Gastric bypass findings could lead to diabetes treatment
9. Into Action Drug Treatment Center Supports the March of Dimes Walk
10. Alzheimer's Treatment Clinical Trial Receives Clearance
11. Atlantic Spine Center Announces Updated Web Content on Spinal Stenosis New Treatments and a Better Approach to Spinal Stenosis Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency ... Series, Outliers in Writing, set to publish in summer 2017. , Dr. Bobrow, ... University of Arizona College of Medicine. He also serves as Medical Director for the ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
Breaking Medicine Technology: